[go: up one dir, main page]

WO2008030524A3 - Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp - Google Patents

Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp Download PDF

Info

Publication number
WO2008030524A3
WO2008030524A3 PCT/US2007/019461 US2007019461W WO2008030524A3 WO 2008030524 A3 WO2008030524 A3 WO 2008030524A3 US 2007019461 W US2007019461 W US 2007019461W WO 2008030524 A3 WO2008030524 A3 WO 2008030524A3
Authority
WO
WIPO (PCT)
Prior art keywords
oral administration
pharmaceutical formulations
liquid pharmaceutical
cgrp antagonist
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019461
Other languages
English (en)
Other versions
WO2008030524A2 (fr
Inventor
David Breslin
Joyce Stellabott
Hossain Jahansouz
Laman L Alani
Karen Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to JP2009527409A priority Critical patent/JP2010502710A/ja
Priority to AU2007293032A priority patent/AU2007293032A1/en
Priority to EP07837821A priority patent/EP2063708A2/fr
Priority to CA002662748A priority patent/CA2662748A1/fr
Publication of WO2008030524A2 publication Critical patent/WO2008030524A2/fr
Publication of WO2008030524A3 publication Critical patent/WO2008030524A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des formulations liquides qui renferment le composé 1-[1-({[(3R,6S)-6-(2,3-difluorophényl)-2-oxo-1-(2,2,2-trifluoroéthyl)azepan-3-yl]amino}carbonyl)pipéridin-4-yl]-2-oxo-1,2-dihydroimidazo[4,5-b]pyridin-3-ide. Les formulations de l'invention possèdent une biodisponibilité et une stabilité étonnament améliorées, en ce qu'elles comprennent du polyéthylène glycol, du Tween (polysorbate 80), du Cremophor® EL (polyoxyle 35-huile de ricin), du propylène glycol et, facultativement, de l'eau, et peuvent être placées dans des capsules de gélatine souple ou dure afin de traiter des troubles, parmi lesquels les maux de tête et les céphalées vasculaires de Horton.
PCT/US2007/019461 2006-09-08 2007-09-06 Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp Ceased WO2008030524A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009527409A JP2010502710A (ja) 2006-09-08 2007-09-06 Ｃｇｒｐ拮抗薬の経口投与のための液体医薬製剤
AU2007293032A AU2007293032A1 (en) 2006-09-08 2007-09-06 Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
EP07837821A EP2063708A2 (fr) 2006-09-08 2007-09-06 Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp
CA002662748A CA2662748A1 (fr) 2006-09-08 2007-09-06 Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84305206P 2006-09-08 2006-09-08
US60/843,052 2006-09-08

Publications (2)

Publication Number Publication Date
WO2008030524A2 WO2008030524A2 (fr) 2008-03-13
WO2008030524A3 true WO2008030524A3 (fr) 2008-10-02

Family

ID=39157840

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019461 Ceased WO2008030524A2 (fr) 2006-09-08 2007-09-06 Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp

Country Status (6)

Country Link
EP (1) EP2063708A2 (fr)
JP (1) JP2010502710A (fr)
CN (1) CN101511184A (fr)
AU (1) AU2007293032A1 (fr)
CA (1) CA2662748A1 (fr)
WO (1) WO2008030524A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526909A (ja) * 2008-06-30 2011-10-20 メルク・シャープ・エンド・ドーム・コーポレイション テルカゲパントカリウムの固形投与製剤
CN101756900B (zh) * 2010-02-25 2012-05-30 谢恬 一种榄香烯微乳
BR112016005589B8 (pt) * 2013-09-16 2023-04-18 Merck Sharp & Dohme Composição farmacêutica líquida, e, uso da mesma
WO2015164657A1 (fr) * 2014-04-23 2015-10-29 Bcs Business Consulting Services Pte Ltd Incorporation de composant(s) soluble(s) dans l'eau dans des formulations anhydres
EA202192793A1 (ru) * 2019-04-11 2022-01-12 Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
PE20251285A1 (es) * 2022-05-11 2025-05-14 Lilly Co Eli Composiciones farmaceuticas de glp1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
WO2004092166A2 (fr) * 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs cgrp

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
WO2004092166A2 (fr) * 2003-04-15 2004-10-28 Merck & Co., Inc. Antagonistes des recepteurs cgrp

Also Published As

Publication number Publication date
CN101511184A (zh) 2009-08-19
WO2008030524A2 (fr) 2008-03-13
CA2662748A1 (fr) 2008-03-13
JP2010502710A (ja) 2010-01-28
EP2063708A2 (fr) 2009-06-03
AU2007293032A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2008030524A3 (fr) Formulations pharmaceutiques liquides pour l'administration orale d'un antagoniste du cgrp
WO2007048026A3 (fr) Antagonistes de peptide cgrp et conjugues
WO2007133752A3 (fr) Procédés de prévention de nausées et de vomissements aigus ou tardifs induits par la chimiothérapie (cinv)
MX2009004461A (es) Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada.
WO2005065319A3 (fr) Forme galenique de fentanyl generalement lineaire effervescente et orale et ses procedes d'administration
WO2005065317A3 (fr) Forme posologique orale effervescente a base de fentanyl et procedes permettant d'administrer du fentanyl
TWI365880B (en) Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
WO2009088414A3 (fr) Formes posologiques pharmaceutiques orales
IL195788A (en) Vegf Antagonist Vascular Endothelial Growth Factor, a method of preparation and an appropriate intravenous injection containing them
WO2005041925A3 (fr) Compositions et formes posologiques permettant une absorption amelioree
WO2008019996A3 (fr) Formulations de flibansérine et leur procédé de fabrication
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
NZ581589A (en) Solubilized sterile injectable formulation of docetaxel without Tween 80
WO2007143155A3 (fr) Forme pharmaceutique à liberation prolongée contenant de la phényléphrine
CA2514224A1 (fr) Formulations pharmaceutiques liquides de palonosetrone
EP1807146A4 (fr) Composition pour l'amelioration de l'efficacite d'administration de medicaments
EP2279732A3 (fr) Composés et compositions pour la distribution d'agents actifs
WO2005117873A3 (fr) Compositions contenant des antagonistes opioides
NO20073551L (no) Nikotinacetylkolinreseptorligander
WO2007133751A3 (fr) Formulations de polyorthoester à base stabilisée
MX2011005643A (es) Formas de dosificacion oral de bendamustina.
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
WO2006058007A3 (fr) Procedes et compositions permettant d'utiliser des inhibiteurs jnk pour traiter et gerer une blessure du systeme nerveux central
IL197732A0 (en) Packaging system for pharmaceutical compositions for intravenous administration and kits comprising the same
IL181872A0 (en) Stable emulsion compositions for intravenous administration having preservative efficacy

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780033097.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837821

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007293032

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1014/CHENP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007293032

Country of ref document: AU

Date of ref document: 20070906

Kind code of ref document: A

Ref document number: 2662748

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009527409

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007837821

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE